Abstract:Selection of the treatments most likely to combat a patient's tumor is a central aim of precision oncology. We are currently developing a functional precision oncology program at the University of Utah and Huntsman Cancer Institute that combines the multi-omic characterization of a patient's tumor with the functional screening of relevant drug candidates in patient-derived organoid tumor models to identify which drugs are uniquely capable of combating the patient's cancer. Here we present our model-based approach for utilizing the multi-omic tumor data to computationally predict the patient's response to each drug. In this approach, we first identify the genomic and transcriptomic vulnerabilities of the tumor as genes harboring somatic DNA mutations or copy number changes (from paired tumor/normal WGS/WES DNA sequencing data), as well as genes whose expression levels have been significantly altered in the tumor (based on bulk or single-cell RNA sequencing data). Second, using targeting information from drug-gene interaction databases (DGIdb) we compile a list of genes targeted by each drug relevant in the patient's treatment. Third, we utilize gene interaction database knowledge (KEGG) to construct a gene interaction graph to link each drug's gene targets with all of the tumor's vulnerability genes. We then identify all gene interaction paths connecting specific drug target genes with specific vulnerability genes; and score each path and combine all path-specific scores for the target-vulnerability gene pair. Subsequently, we further combine all pairwise scores across all drug target genes and all tumor vulnerability genes and determine the statistical significance of the resulting score by sampling the background distribution of such scores across random drugs, target genes, and vulnerability genes. We have applied our algorithm to predict drug response in advanced breast cancer patients as well as using publicly available tumor cell line data (GDSC2). We have found a high level of concordance between our computational prediction and organoid/cell line screening results, clearly separating sensitive and non-sensitive models. Using Bayesian probability, we compare the drug-specific score distributions of sensitive and non-sensitive models and are able to identify sensitive cell lines/patients with high accuracy. By encapsulating available information on direct gene-gene interactions, the drug's direct gene targets and the collected omic vulnerabilities of the tumor, our model is not only capable of predicting sensitivity to both targeted and chemotherapy agents, but can also provide a mechanistic understanding for the targeting of the tumor. Our approach will be validated and fine-tuned on a large cohort of breast and brain cancer patients as well as patient PDX models, interrogating gene-target interactions to identify novel relevant target genes/pathways. Citation Format: Szabolcs Tarapcsak, Yi Qiao, Xiaomeng Huang, Tony Di Sera, Matthew H. Bailey, Bryan E. Welm, Alana L. Welm, Gabor T. Marth. Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2723.

A Theoretical Model for Predicting and Optimizing in Vitro Screening of Potential Targeted Alpha-Particle Therapy Drugs

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Advances in models predicting efficacy of immune checkpoint inhibitors

Prediction Of Treatment Efficacy For Prostate Cancer Using A Mathematical Model

Data-based modeling of breast cancer and optimal therapy

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

Prediction of Cancer Patient Responses to Different Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles.

A Novel Mathematical Model for Quantitatively Analyzing Radiobiological Response

Mathematical Modeling of the Synergetic Effect between Radiotherapy and Immunotherapy

Improving the predictive accuracy of efficacy evaluation using tumor orthotopic transplant and resection model

Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy

Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of in Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.

Based on Nucleotides Analysis of Tumor Cell Lines to Construct and Validate a Prediction Model of Mechanisms of Chemotherapeutics.

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy Via Noninvasive Pet Molecular Imaging Strategies of Multifactorial Bioparameters

Microdosimetry for Targeted Alpha Therapy of Cancer

An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice

Growth‐rate model predicts in vivo tumor response from in vitro data

Modeling of Ionizing Radiation-Induced Chromosome Aberration and Tumor Prevalence Based on Two Classes of DNA Double-Strand Breaks Clustering in Chromatin Domains.

LC-MS Based Cell Metabolic Profiling of Tumor Cells: a New Predictive Method for Research on the Mechanism of Action of Anticancer Candidates